Abbott Bets On China With New Nutritional Plant
This article was originally published in PharmAsia News
Abbott Laboratories Inc. announced Aug. 16 it will build a $230 million nutritional manufacturing plant in Jiaxing, China, its largest investment to date in the country
You may also be interested in...
The Belgian biotech has managed to attract considerable sums from venture capitalists over the past couple of years amid hopes that its two next-generation immunotherapies will be best-in-class agents.
Cipla is celebrating an “important milestone” for the company after the successful completion of a Phase III clinical trial comparing its proposed Advair generic with GSK’s brand in the US. Management has cautioned that approval will be a way off yet, however.
FDA requests immediate removal of ranitidine OTC and Rx drugs after third-party testing finds contaminant NDMA increases during storage, especially at higher temperatures. CDER Director Janet Woodcock asks firms to reformulate products to be stable as the ingredient remains approved.